10x Genomics (TXG) Competitors

Mirion Technologies (NYSE:MIR) and 10x Genomics (NASDAQ:TXG) are both business services companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.

Do analysts prefer MIR or TXG?

Mirion Technologies presently has a consensus price target of $18.00, indicating a potential upside of 29.34%. 10x Genomics has a consensus price target of $19.79, indicating a potential upside of 142.47%. Given 10x Genomics' higher possible upside, analysts plainly believe 10x Genomics is more favorable than Mirion Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirion Technologies	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.40
10x Genomics	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.35

Does the MarketBeat Community believe in MIR or TXG?

10x Genomics received 44 more outperform votes than Mirion Technologies when rated by MarketBeat users. However, 85.71% of users gave Mirion Technologies an outperform vote while only 51.24% of users gave 10x Genomics an outperform vote.

Company	Underperform	Outperform
Mirion Technologies	Outperform Votes 18 85.71%	Underperform Votes 3 14.29%
10x Genomics	Outperform Votes 62 51.24%	Underperform Votes 59 48.76%

Do institutionals and insiders believe in MIR or TXG?

78.5% of Mirion Technologies shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 2.2% of Mirion Technologies shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has more volatility and risk, MIR or TXG?

Mirion Technologies has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Which has better valuation and earnings, MIR or TXG?

Mirion Technologies has higher revenue and earnings than 10x Genomics. Mirion Technologies is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirion Technologies	$860.80M	3.76	-$36.10M	-$0.19	-73.25
10x Genomics	$610.79M	1.63	-$182.63M	-$1.52	-5.37

Does the media favor MIR or TXG?

In the previous week, 10x Genomics had 15 more articles in the media than Mirion Technologies. MarketBeat recorded 19 mentions for 10x Genomics and 4 mentions for Mirion Technologies. 10x Genomics' average media sentiment score of 0.69 beat Mirion Technologies' score of 0.58 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirion Technologies	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
10x Genomics	6 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Is MIR or TXG more profitable?

Mirion Technologies has a net margin of -4.21% compared to 10x Genomics' net margin of -29.90%. Mirion Technologies' return on equity of 4.78% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirion Technologies	-4.21%	4.78%	2.81%
10x Genomics	-29.90%	-25.40%	-19.69%

Summary

Mirion Technologies beats 10x Genomics on 10 of the 19 factors compared between the two stocks.